Rationale and prospects of mesenchymal stem cell therapy for liver transplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 1, 2014, Pages 60-64

  Obermajer, Nataša ^a   Popp, Felix C ^b   Johnson, Christian L ^b   Benseler, Volker ^b   Dahlke, Marc H ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

immunosuppression; liver transplantation; mesenchymal stem cells; regeneration; tolerance; transdifferentiation

Indexed keywords

EID: 84895901203     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000031     Document Type: Review

References (45)

1. Grinyo JM, Cruzado JM. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress. Am J Transplant 2009; 9:2447-2452.
2. Frank B, Perdrizet GA, White HM, et al. Neurotoxicity of FK 506 in liver transplant recipients. Transplant Proc 1993; 25:1887-1888.
3. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125:1747-1754.
4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-317.
5. Bacchella T, Galvao FH, Jesus de Almeida JL, et al. Marginal grafts increase early mortality in liver transplantation. Sao Paulo Med J 2008; 126:161-165.
6. Schlitt HJ, Loss M, Scherer MN, et al. Aktuelle Entwicklungen der Lebertransplantation in Deutschland: MELD-basierte Organallokation und 'incentives' fur Transplantationszentren[Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres]. Z Gastroenterol 2011; 49:30-38.
7. Briceno J, Marchal T, Padillo J, et al. Influence of marginal donors on liver preservation injury. Transplantation 2002; 74:522-526.
8. English K, Wood KJ. Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med 2013; 3:a015560.
9. English K, Mahon BP, Wood KJ. Mesenchymal stromal cells; role in tissue repair, drug discovery and immune modulation. Curr Drug Deliv 2013. [Epub ahead of print]
10. Crop MJ, Baan CC, Korevaar SS, et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162:474-486.
11. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002; 109:1291-1302.
12. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999; 284:1168-1170.
13. Snykers S, Vanhaecke T, Papeleu P, et al. Sequential exposure to cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells. Toxicol Sci 2006; 94:330-341; discussion 235-239.
14. Krampera M, Pasini A, Pizzolo G, et al. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006; 6:435- 441.
15. Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev 2013; 9:65-79.
16. Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12:2373-2383.
17. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181:3933-3946.
18. Roddy GW, Oh JY, Lee RH, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-Alpha stimulated gene/protein 6. Stem Cells 2011; 29:1572-1579.
19. Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3:297.
20. Eggenhofer E, Steinmann JF, Renner P, et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol 2011; 24:157-163.
21. Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011; 25:141-147.
22. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9:1760-1772.
23. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20:55-60.
24. Eggenhofer E, Popp FC, Mendicino M, et al. Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression. Stem Cells Transl Med 2013; 2:595-606.
25. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
26. Perico N, Casiraghi F, Gotti E, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013; 26:867-878.
27. Wang Y, Zhang A, Ye Z, et al. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc 2009; 41:4352-4356.
28. KimYH,WeeYM,Choi MY, et al. Interleukin (IL)-10 induced byCD11b(R) cells and IL-10-Activated regulatory T cells play a role in immune modulation of mesenchymal stemcells in rat islet allografts. Mol Med 2011; 17:697- 708.
29. Kuo YR, Chen CC, Goto S, et al. Immunomodulatory effects of bone marrowderived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One 2012; 7:e35459.
30. Ge W, Jiang J, Arp J, et al. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90:1312- 1320.
31. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 2013; 18:51-58.
32. Carlin AM, Zeni TM, English WJ, et al. The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. Ann Surg 2013; 257:791- 797.
33. Birkmeyer NJ, Finks JF, English WJ, et al. Risks and benefits of prophylactic inferior vena cava filters in patients undergoing bariatric surgery. J Hosp Med 2013; 8:173-177.
34. Franquesa M, Hoogduijn MJ, Baan CC. The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Curr Opin Organ Transplant 2012; 17:355-361.
35. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013; 91:19-26.
36. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
37. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 2013; 95:161-168.
38. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
39. Dahlke MH, Hoogduijn M, Eggenhofer E, et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation 2009; 88:614-619.
40. Franquesa M, Hoogduijn MJ, Reinders ME, et al. Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. Transplantation 2013; 96:234-238.
41. Dillmann J, Popp FC, Fillenberg B, et al. Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation. Trials 2012; 13:211.
42. Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation - a phase I study (MISOT-I). J Transl Med 2011; 9:124.
43. Kovacsovics-Bankowski M, Mauch K, Raber A, et al. Preclinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 2008; 10:730-742.
44. Boozer S, Lehman N, Lakshmipathy U, et al. Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell. J Stem Cells 2009; 4:17-28.
45. Van Bokkelen G. Company profile: Athersys. Regen Med 2011; 6:39-43.